Regeneron Pharmaceuticals Inc. buy Evercore ISI
Start price
14.05.24
/
50%
€909.80
Target price
14.05.25
€1,064.2
Performance (%)
-1.52%
Price
30.05.24
€896.00
Summary
This prediction is currently active. With a performance of -1.52%, the BUY prediction for Regeneron Pharmaceuticals Inc. by Evercore_ISI is down slightly. This prediction currently runs until 14.05.25. The prediction end date can be changed by Evercore_ISI at any time. Evercore_ISI has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Regeneron Pharmaceuticals Inc. | -1.256% |
| iShares Core DAX® | -0.530% |
| iShares Nasdaq 100 | -0.580% |
| iShares Nikkei 225® | -1.097% |
| iShares S&P 500 | -0.730% |
Comments by Evercore_ISI for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $1,150.00 price target on the stock.
Ratings data for REGN provided by MarketBeat
Stopped prediction by Evercore_ISI for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€899.00
16.05.24
16.05.24
-
16.05.25
16.05.25
-0.33%
30.05.24
30.05.24
